Literature DB >> 23824658

Unique and selective expression of L-amino acid transporter 1 in human tissue as well as being an aspect of oncofetal protein.

Norihiro Nakada1, Tetuo Mikami2, Kiyomi Hana3, Masaaki Ichinoe2, Nobuyuki Yanagisawa2, Tsutomu Yoshida4, Hitoshi Endou5, Isao Okayasu4.   

Abstract

Dysregulated expression of L-type amino acid transporter 1 (LAT1), which transports large neutral amino acids, is a characteristic of various human cancers and possibly offers a molecular target for chemotherapy. LAT2, in contrast, shows lower expression in neoplasms. LAT1 is presumed to be a biomarker of many cancers, suggesting a kind of oncoprotein. However, no precise analysis of LAT1 and LAT2 expression has been performed in systemic normal tissues. To see characteristics of LAT1 and LAT2, immunohistochemical expression of LAT1 and LAT2 was assessed and compared in normal human systemic organs and tissues from 3 adults, 3 children and 3 fetuses in the present study. Cardiac muscles, hepatocytes, thymic epithelial cells and primitive neuroectodermal cells in fetus were positive with LAT1, whereas no expression was found in the respective adult tissues, indicating an aspect of oncofetal protein. In adult tissues, LAT1 was found to be expressed proximal to proliferative zones in gastrointestinal mucosa by double immunostaining of LAT1 and Ki-67. Testicular Sertoli cells, ovarian follicular cells, and pancreatic islet cells showed strong expression. Although the systemic capillary endothelium did not express LAT1, but did express LAT2, capillaries corresponding to the blood-brain, blood-follicle, and blood-retinal barriers demonstrated strong LAT1 immunoreactions. In conclusion, LAT1 was expressed in gonad tissues and several kinds of cells having special functions, as well as being discovered to be an aspect of oncofetal protein. In addition, ubiquitous LAT2 expression was confirmed immunohistochemically in systemic tissues, indicating constitutional function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23824658     DOI: 10.14670/HH-29.217

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  11 in total

1.  Structural insights into thyroid hormone transport mechanisms of the L-type amino acid transporter 2.

Authors:  Katrin M Hinz; Katja Meyer; Anita Kinne; Ralf Schülein; Josef Köhrle; Gerd Krause
Journal:  Mol Endocrinol       Date:  2015-05-06

2.  18F-FBPA as a tumor-specific probe of L-type amino acid transporter 1 (LAT1): a comparison study with 18F-FDG and 11C-Methionine PET.

Authors:  Tadashi Watabe; Hayato Ikeda; Shushi Nagamori; Pattama Wiriyasermkul; Yoko Tanaka; Sadahiro Naka; Yasukazu Kanai; Kohei Hagiwara; Masanao Aoki; Eku Shimosegawa; Yoshikatsu Kanai; Jun Hatazawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-22       Impact factor: 9.236

3.  First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors.

Authors:  Naohiro Okano; Daisuke Naruge; Kirio Kawai; Takaaki Kobayashi; Fumio Nagashima; Hitoshi Endou; Junji Furuse
Journal:  Invest New Drugs       Date:  2020-03-20       Impact factor: 3.850

Review 4.  Heteromeric Solute Carriers: Function, Structure, Pathology and Pharmacology.

Authors:  Stephen J Fairweather; Nishank Shah; Stefan Brӧer
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB0,+, LAT1 and LAT2.

Authors:  Printip Wongthai; Kohei Hagiwara; Yurika Miyoshi; Pattama Wiriyasermkul; Ling Wei; Ryuichi Ohgaki; Itsuro Kato; Kenji Hamase; Shushi Nagamori; Yoshikatsu Kanai
Journal:  Cancer Sci       Date:  2015-03-06       Impact factor: 6.716

Review 6.  Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment.

Authors:  Keitaro Hayashi; Naohiko Anzai
Journal:  World J Gastrointest Oncol       Date:  2017-01-15

7.  CD44 variant inhibits insulin secretion in pancreatic β cells by attenuating LAT1-mediated amino acid uptake.

Authors:  Nana Kobayashi; Shogo Okazaki; Oltea Sampetrean; Junichiro Irie; Hiroshi Itoh; Hideyuki Saya
Journal:  Sci Rep       Date:  2018-02-12       Impact factor: 4.379

8.  Amino Acid Transporters as Potential Therapeutic Targets in Thyroid Cancer.

Authors:  Keisuke Enomoto; Muneki Hotomi
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

9.  Evaluation of the total distribution volume of 18F-FBPA in normal tissues of healthy volunteers by non-compartmental kinetic modeling.

Authors:  Victor Romanov; Kayako Isohashi; Galal Alobthani; Rouaa Beshr; Genki Horitsugi; Yasukazu Kanai; Sadahiro Naka; Tadashi Watabe; Eku Shimosegawa; Jun Hatazawa
Journal:  Ann Nucl Med       Date:  2019-12-05       Impact factor: 2.668

10.  High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas.

Authors:  Nobuyuki Yanagisawa; Kiyomi Hana; Norihiro Nakada; Masaaki Ichinoe; Wasaburo Koizumi; Hitoshi Endou; Isao Okayasu; Yoshiki Murakumo
Journal:  Cancer Med       Date:  2014-06-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.